Company: FVN
Filing Date: 2025-02-14
Form Type: DRS/A
Source: 0001829126-25-000945
Chunk: 109

Company: Future Vision II Acquisition Corp.
Filing Date: 2025-02-14
Form: DRS/A
Chunk 109
---
 and should complete the filing before the completion of their overseas offering and listing; (ii) a six-month transition period will be granted to PRC domestic companies which, prior to the effective date of the Trial Measures, have already obtained the approval from overseas regulatory authorities or stock exchanges (such as the completion of registration in the market of the United States), but have not completed the indirect overseas listing; and follow-on offerings of such companies will need to comply with the Trial Measures.

Based on the advice of our PRC counsel, as our PRC Subsidiaries accounted for more than 50% of our consolidated revenues, profit, total assets or net assets for the fiscal years ended September 30, 2023 and 2024, and the key components of our operations are carried out in the PRC, this Business combination is considered an indirect offering and we are subject to the filing requirements under the Trial Measures. This Business combination and our listing on Nasdaq are therefore contingent on our completion of the filing procedures with the CSRC under the Trial Measures. We had submitted the filing application with the CSRC on December 4, 2024 but CSRC has not yet notified us that they have completed review, and we may be required to supplement our filing with additional information. There is no assurance that we can complete the filing with the CSRC in compliance with the Trial Measures prior to our listing on Nasdaq. If we fail to comply with the Trial Measures, the CSRC may order rectification, issue warnings, and impose a fine between RMB 1.0 million ($0.15 million) and RMB 10.0 million ($1.5 million) on our company. The Trial Measures may subject us to additional compliance requirement in the future, and we cannot assure you that we will be able to get the clearance of the CSRC filing procedures under the Trial Measures on a timely basis, or at all. Any failure of us to fully comply with new regulatory requirements may significantly limit or completely hinder our ability to offer or continue to offer our ordinary shares, cause significant disruption to our business operations, and severely damage our reputation, which would materially and adversely affect our financial condition and results of operations and cause our ordinary shares to significantly decline in value or become worthless.

<div align='center'>60</div>

Changes in China’s economic, political or social conditions or government policies could have a material adverse effect on VIWO’s business, financial condition and results of operations.

Substantially most of VIWO’s revenues are generally